Citadel Advisors’s GlucoTrack GCTK Stock Holding History

Citadel Advisors’s Portfolio GCTK Stock Details GCTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$25.4K	Buy	+5,302	New	+$49.9K	﹤0.01%	13346
2024 Q2	–	Hold	0	–	-$7.27K	–	14677
2024 Q1	–	Hold	0	–	–	–	13623
2023 Q4	–	Hold	0	–	–	–	13113
2023 Q3	–	Hold	0	–	–	–	13195

Other funds holding GCTK

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

GIPW

Granite Islands Private Wealth Guilford, Connecticut $135M AUM

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Citadel Advisors's GCTK Position: Q2 2026 in Review

Citadel Advisors opened a new position in GlucoTrack (GCTK) in Q2 2026: 5,302 shares worth $25.4K. The stake represents ﹤0.01% of the portfolio and ranks #13346 among its holdings.

18 funds tracked by Wall St. Rank hold GCTK as of Q2 2026.

Citadel Advisors held 5,302 shares of GlucoTrack worth $25.4K as of Q2 2026.
GlucoTrack was a new Citadel Advisors position in Q2 2026.
GlucoTrack made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #13346 holding.
18 funds tracked by Wall St. Rank held GlucoTrack as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.